---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000041"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-06-16T13:05:18+00:00"
generated_at: "2026-06-16T13:06:21.385358+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncolytics secures new U.S. patent for pelareorep manufacturing through 2044; method-of-use app to 2046

## Summary
- USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.
- Previously filed method-of-use patent application under review, if issued would protect into 2046.
- Company plans additional patent filings in 2026 to expand IP across therapeutic applications and combinations.
- CEO states patent supports commercial-scale production and long-term value of pelareorep.

## SEC filing metadata
- accession: 0001129928-26-000041
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-06-16T13:05:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000041/0001129928-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000041/oncy-20260616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000041
- JSON: https://secwatch.observer/filing/0001129928-26-000041.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.